



Mylan N.V.  
Investor Relations Department  
PO Box 2648  
Portland, OR 97208-2648  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: MYL**

Last Trade:	39.03
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	33.60 - 50.40
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 10, 2017*

[Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions](#)

*Jun 7, 2017*

[Mylan to Present at Goldman Sachs 38th Annual Global Healthcare Conference](#)

*Jun 2, 2017*

[Mylan Launches Generic Azilect® Tablets](#)

*Jun 2, 2017*

[Mylan Launches Generic Reclast® Injection](#)

*May 23, 2017*

[Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin \(TD-4208\) in Several Presentations at 2017 ATS](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*May 23, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)